CMPX - יחס חוב להיוון בספרים Compass Therapeutics

The business specifics of Compass Therapeutics (CMPX) are not tied to economic cycles, as demand for tumor therapy remains stable and success depends on R&D and funding, which currently stands at 0.06. This price chart on GURU.Markets points toward a strategy of creating innovative antibodies, where the priority is bringing the CTX-009 drug for the treatment of biliary tracts to market. Development relies on scientific partnerships without major mergers.

For the investor, this ratio serves as a measure of financial stability, reflecting the dependence of equity on external liabilities. Amid the development of immunotherapy through alliances and M&A, the share of debt financing in the balance sheet capitalization demonstrates how aggressively Compass Therapeutics (CMPX) borrows funds to acquire patents. A decrease in this indicator confirms the company's ability to sustain scientific research and development without a critical increase in credit pressure.